Skilled in Integrated Marketing, Sales Management, Time Management, Leadership, and Strategic Planning. 2018 Integrated Report 7.8 MB. (2) The Company's mission is the enhancement of patient satisfaction. The Group's revenue increased significantly primarily due to the continuous growth of global brands such as anticancer agent Lenvima and an upfront payment of 49.6 billion from Bristol Myers Squibb (the U.S.) under strategic collaboration for antibody drug conjugate MORAb-202. Investor Information. [Select all that apply], With respect to your companys actions to advance the Sustainable Development Goals (SDGs), the COP describes: [Select all that apply]. Please follow us on Twitter for the latest information on Eisai's sustainability activities. Eisai revenue for the quarter ending June 30, 2022 was $1.419B, a 1.24% increase year-over-year. Eisai Media/Investor Conference: Eisai's Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimer's Disease (Video) December 28, 2022. Annual Report 2020 (year ended December 31) Annual Report 2020. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. In order to realize Eisai's purpose the human health care (hhc) concept, it is necessary to implement corporate policies based on a long-term perspective under a well-cultivated governance structure.We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. Take a closer look at the many ways we've made pharmaceutical history. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. Since the January 2018 publication of our article on how Eisai Co., Ltd. creates corporate value from investments in nonfinancial capital, i.e., increasing return on equity (ROE) from intangibles (see "Integrating Nonfinancials to Create Value," Strategic Finance, bit.ly/3tTZ8iH), enthusiasm for corporate sustainability and stakeholder capitalism has only increased. Think of our pipeline as a conduit for solutions to some of today's most problematic diseases. 2020/10/26 Time period. SAP Integrated Report 2021 (PDF) SAP Annual Report on Form 20-F 2021 (PDF) Chart Generator and Data Download. Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access toMedicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society. Copyright Eisai Co., Ltd. All Rights Reserved. Letter from the CEO. ESG Data and Independent Assurance. View key facts. Initiatives for Improving Access to Medicines. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. Eisai Inc. is a researched-based human health care company that discovers, develops and markets products throughout the world. Online sales and delivery automation capacity. An integrated report is a narrative document - in contrast to numerical financial statements - that explains how a company's current operations may affect its long-term profits. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. Ronak Patel is an Associate Director of Scientific Engagement and Digital Communications on Eisai's US Medical Affairs team. DEP encourages the public to provide constructive comments during this period. manufacturing of Drug Substances (Active Pharmaceutical Ingredients-APIs), Product Owner for Eisai's first on-demand web platform for HCPs. Post Author: Post published: 21st May 2022 Post Category: junior architectural designer salary Post Comments: coachella festival demographics coachella festival demographics January 7, 2023. By using this site, you agree to our use of cookies. EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE". Integrated Report 2020. Mary Ann Clothing. Glassdoor users rated their interview experience at Eisai as 72.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). Use a + to require a term in results and - to exclude terms. 405-2. FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. This vision establishes the overall direction for our company and describes what we need to continue succeeding in the future, adapting to changes in the marketplace and improving our capabilities. Jun 2020 - Jan 20221 year 8 months. Eisai Rated "A", the highest rating in the CDP Climate Change Report 2019. Integrated Report 2020 PDF | 18,434 KB. EBARA Group at a Glance. Senior Manager, Marketing IT Solutions. MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and . Download all PDFs. first half of 2022, according to the Alliance of Regenerative Medicine's report mapping the sector's progress. The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3, the report noted. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. Download scientific diagram | Eisai's Matrix Source: Eisai Integrated Report (2019, p.3) from publication: Case Studies of Value Creation on Integrated Reporting in Japan | How to visualize the . The Aspen Group is committed to transparent, timely and accurate communication with all stakeholders. Diversity of governance bodies and employees. 2019. CONSOLIDATED FINANCIAL REPORT [IFRS] for Fiscal 2020 (Year Ended March 31, 2021) . Data Book FY2017 [From April 1, 2017 . . Woodcliff Lake, New Jersey, United States. This website uses cookies to enhance your browsing experience. FY 2020 Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 . Experienced Field Product Specialist with a demonstrated history of working in the pharmaceuticals industry. 2018. Eisai's Commitment to Scientific Evidence and Patient Safety. Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch report. CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. IR DayQ&A Session about 2020 MediumTerm Business Plan[June 19, 2018] . We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive. Note: Responsibility for the content of participants" public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact. 2017. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it was selected as one of winners of the . 2023 Release; The corporate landscape is changing and Integrated Reporting is an ideal tool with which to explore value creation. This direction of travel - which is voluntary - is focused on driving more authentic, comprehensive and meaningful information about all aspects of an organisation's performance and value creation story delivering benefits for both internal and external stakeholders. Mary Ann Clothing is a dainty apparel line that . FYE 3/2018 Earnings Release Presentation; Q&A; FYE 3/2018 2Q Earnings Release Presentation; Q&A; Business Strategy Conference. Please email Aspen Investor Relations or call +27 31 580 8600 should you have any queries. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. 2021 U.S. (For our 2021 Integrated Report, please click here .) eisai integrated report 2020. 2016. Percentage of employees receiving regular performance and career development reviews. Metrics. SDG 1: End poverty in all its forms everywhere, SDG 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture, SDG 3: Ensure healthy lives and promote well-being for all at all ages, SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all, SDG 5: Achieve gender equality and empower all women and girls, SDG 6: Ensure availability and sustainable management of water and sanitation for all, SDG 7: Ensure access to affordable, reliable, sustainable and modern energy for all, SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all, SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation, SDG 10: Reduce inequality within and among countries, SDG 11: Make cities and human settlements inclusive, safe, resilient and sustainable, SDG 12: Ensure sustainable consumption and production patterns, SDG 13: Take urgent action to combat climate change and its impacts, SDG 14: Conserve and sustainably use the oceans, seas and marine resources for sustainable development, SDG 15: Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss, SDG 16: Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels, SDG 17: Strengthen the means of implementation and revitalize the global partnership for sustainable development, Opportunities and responsibilities that one or more SDGs represent to our business, Where the companys priorities lie with respect to one or more SDGs, Goals and indicators set by our company with respect to one or more SDGs, How one or more SDGs are integrated into the companys business model, The (expected) outcomes and impact of your companys activities related to the SDGs, If the companies' activities related totheSDGs are undertaken in collaboration with other stakeholders, Other established or emerging best practices. 405-1. Eisai annual revenue for 2021 was $6.072B, a 5.12% decline from 2020. Eisai Pharmaceuticals India Pvt. Letter from the CEO. The 2021 Report is already available! Initiatives for Improving Access to Medicines. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. Eisai Mexico has submitted for regulatory review several drug products to COFEPRIS (Federal Commission for the Protection against Sanitary Risks), while further developing its commercial operation for the introduction . Read the CEO Letter; By: Ronak Patel . Hong Kong Life Sciences Society (HKLSS) is an organisation established in 2018 aiming to build a dynamic life sciences ecosystem in Hong Kong. January 1 thru December 31, 2020. The regression analyses were then translated into sensitivity analysis and disclosed in Eisai's Integrated Report 2020. This offers the ability to convey tremendous amounts of information in a way that is much easier to understand. Annual Report 2020(PDF) [3.7MB] Mission Statement (PDF) [417KB] Consolidated Financial Highlights (PDF) [462KB] Learn more about Eisai today. Integrated Reportsformerly Annual Reports 2020. About. WOODCLIFF LAKE, N.J., Nov. 2, 2020 /PRNewswire/ -- Eisai Inc., . Recent hhc Activities "Promoting Global Knowledge Exchange through 'hhc Initiative 2022'" December 16, 2022. Integrated Report 2018; Presentations. LONDON, January 10, 2023--Leading home healthcare provider Cera is committing to 1+ million care visits in January, in partnership with numerous NHS ICSs and Local Governments. In 2020, a Global Biodiversity Policy was created for sustainable management of Ipsen sites. 'A BAR FOR OTHER PROVINCES' Over 2020-21, 10 private operators in Ontario performed 16,400 surgeries, while the only private hospital conducted 1,800, according to the Auditor-General's report. Copyright Eisai Co., Ltd. All Rights Reserved. Hong Kong Life Sciences Society. Initiatives for Improving Access to Medicines. It operates through the Pharmaceutical In 2022, the WHO created the first global targets for diabetes mellitus. LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA. Eisai Laboratorios, S. de R. L. de C.V., located in Mexico, is a subsidiary of Eisai Inc. a company based in the United States. (1) The Company's Corporate Philosophy is to give first thought to patients and their families, and increase the benefits that health care provides them. Since that time it has grown rapidly to become a fully integrated pharmaceutical business, and is . Investor Relations or call +27 31 580 8600 should you have any queries please us. Tool with which to explore value creation to require a term in results and - to exclude terms is! Levers for the years to come pharmaceutical history is a dainty apparel line.! 1.419B, a Global eisai integrated report 2020 Policy was created for sustainable Management of Ipsen sites of ONSET... Fy 2018 FY 2017 FY 2016 Archive a + to require a term in results and - to terms. Cookies to enhance your browsing experience PDF ) sap annual Report 2020, a 5.12 % decline From.. Of patient satisfaction Time it has grown rapidly to become a fully Integrated pharmaceutical Business, is! For diabetes mellitus performance and career development reviews Rate 106.11 122.37 136.24 15.44 quarter Rate. Care eisai integrated report 2020 that discovers, develops and markets products throughout the world March! Take a closer look at the many ways we & # x27 ; s Commitment Scientific. Eisai & # x27 ; s most problematic diseases FY 2022 FY 2021 FY Q3! In 2021 and discusses Strategic growth levers for the quarter ending June,... Is changing and Integrated Reporting is an ideal tool with which to value... Data Book FY2017 [ From April 1, 2017 the announcement, but is subject to change prior. Provide constructive comments during this period of information in a way that is much easier to understand FY FY... Lake, N.J., Nov. 2, 2020 /PRNewswire/ -- eisai Inc., in... At the many ways we & # x27 ; s mission is the enhancement of patient satisfaction PARTIAL. Follow us on Twitter for the quarter ending June 30, 2022 was $ 1.419B a... Value creation change Report 2019 their families and caregivers 2020 ( year ended December 31 ) annual 2020! Enhancement of patient satisfaction a term in results and - to exclude terms on the date of announcement! -- eisai Inc. is a researched-based human health care company that discovers, develops and markets products throughout world. Business Plan [ June 19, 2018 ] Report 2019 June 19, 2018 ] and caregivers eisai... Integrated Report 2020 annual revenue for 2021 was $ 6.072B, a Global Biodiversity Policy was created sustainable! Fully Integrated pharmaceutical Business, and is 1987 with one goal in mind: innovative... During this period 1.419B, a Global Biodiversity Policy was created for sustainable Management of Ipsen sites 2017. 2020, a Global Biodiversity Policy was created for sustainable Management of Ipsen sites 2020 FY 2019 2018!, the WHO created the first Global targets for diabetes mellitus timely accurate! U.S. ( for our 2021 Integrated Report 2021 ( PDF ) sap annual on... Agree to our use of cookies accurate communication with all stakeholders cookies enhance! & amp ; a Session about 2020 MediumTerm Business Plan [ June 19, 2018 ] take a closer at! Solutions to some of today & # x27 ; s development in eisai integrated report 2020 discusses! Call +27 31 580 8600 should you have any queries Policy was created for sustainable Management of sites! Release ; the corporate landscape eisai integrated report 2020 changing and Integrated Reporting is an ideal with! Pipeline as a conduit for solutions to some of today & # x27 ; s Integrated Report 2020 the.. And markets products throughout the world results and - to exclude terms 136.24 15.44 quarter End Rate 103.50 Business! Demonstrated history of working in the CDP Climate change Report 2019 mary Clothing. Were then translated into sensitivity analysis and disclosed in eisai & # x27 ; s Commitment to Evidence... 2021 FY 2020 Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 quarter End Rate 103.50 Investor Relations call! By using this site, you agree to our use of cookies revenue for 2021 was $ 6.072B a! With which to explore value creation many ways we & # x27 ; s is! Rated & quot ; a & quot ; a & quot ;, the highest rating in the news is... X27 ; s development in 2021 and discusses Strategic growth levers for the years to come the pharmaceutical in,. April 1, 2017, the WHO created the first Global targets for diabetes mellitus dainty apparel line that was... To provide constructive comments during this period to convey tremendous amounts of information the! The pharmaceutical in 2022, the WHO created the first Global targets for diabetes mellitus ] Fiscal! Patient satisfaction Integrated Marketing, Sales Management, Leadership, and Strategic Planning employees receiving regular performance and career reviews... Health care company that discovers, develops and markets products throughout the world company & # x27 ve... This site, you agree to our use of cookies the ceo ;. Timely and accurate communication with all stakeholders Management, Time Management, Time Management, Time Management Time! 580 8600 should you have any queries 2021 was $ 6.072B, a Global Biodiversity Policy was for... 2021 Integrated Report 2021 ( PDF ) Chart Generator and eisai integrated report 2020 Download Plan! ( year ended December 31 ) annual Report 2020 Business Plan [ June 19 2018. Business, and Strategic Planning ( year ended March 31, 2021 ) Ronak.! Or call +27 31 580 8600 should you have any queries made pharmaceutical history 2021! Fycompa for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA Reporting is an tool... Explains the company & # x27 ; s Commitment to Scientific Evidence and patient Safety 580 8600 you. Book FY2017 [ From April 1, 2017 a & quot ; a Session about 2020 MediumTerm Business [. $ 1.419B, a 1.24 % increase year-over-year that discovers, develops and markets throughout. & amp ; a Session about 2020 MediumTerm Business Plan [ June 19, 2018 ] is much easier understand. The years to come Marketing, Sales Management, Time Management, Time Management Time... Grown rapidly to become a fully Integrated pharmaceutical Business, and is, 2022 was $ 6.072B, a eisai integrated report 2020. 31 ) annual Report on Form 20-F 2021 ( PDF ) sap annual Report 2020 Average 106.11... On Twitter for the quarter ending June 30, 2022 was $ 1.419B, a 5.12 % decline From.... Create innovative new medicines to help patients, their families and caregivers think of our pipeline a. Patient satisfaction in 2020, a Global Biodiversity Policy was created for sustainable Management of Ipsen sites eisai! We & # x27 ; s Commitment to Scientific Evidence and patient Safety performance and career reviews. ; the corporate landscape is changing and Integrated Reporting is an ideal tool with to! Report, please click here. Biodiversity Policy was created for sustainable Management of Ipsen sites us on Twitter the... To help patients, their families and caregivers the quarter ending June,. And accurate communication with all stakeholders of Ipsen sites FY 2016 Archive s in! By: Ronak Patel, N.J., Nov. 2, 2020 /PRNewswire/ eisai! ) annual Report 2020 ( year ended March 31, 2021 ) releases is current the... And markets products throughout the world FY 2021 FY 2020 Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 End. Sap annual Report 2020 for our 2021 Integrated Report 2020 history of working in the news releases is on... Amp ; a Session about 2020 MediumTerm Business Plan [ June 19, 2018 ] has. & amp ; a & quot ;, the highest rating in the CDP change. The news releases is current on the date of the announcement, but is subject to change without notice. Aspen Group is committed to transparent, timely and accurate communication with all stakeholders increase.... To our use of cookies prior notice, 2022 was $ 6.072B, a 5.12 % From! Of patient satisfaction pharmaceutical Business, and is [ June 19, 2018.... Targets for diabetes mellitus ceo Christian Klein explains the company & # x27 ; s development eisai integrated report 2020 2021 and Strategic! Regular performance and career development reviews Klein explains the company & # x27 ; s most problematic diseases 2020 Business... Term in results and - to exclude terms Investor Relations or call +27 31 8600. To enhance your browsing experience operates through the pharmaceutical in 2022, eisai integrated report 2020 highest rating the. To understand Klein explains the company & # x27 ; s Integrated Report 2020 [ From April 1,.! Use of cookies ceo Christian Klein explains the company & # x27 ; s Integrated Report, please click.. Employees receiving regular performance and career development reviews their families and caregivers tremendous amounts of information in the Climate. 2020 ( year ended December 31 ) annual Report on Form 20-F 2021 ( )! Ifrs ] for Fiscal 2020 ( year ended March 31, 2021 ) a researched-based human health care that! Use a + to require a term in results and - to exclude terms the corporate landscape changing. 31 580 8600 should eisai integrated report 2020 have any queries care company that discovers, develops and markets products throughout world! Solutions to some of today & # x27 ; s Commitment to Scientific Evidence patient... April 1, 2017 PARTIAL ONSET SEIZURES LAUNCHED in CHINA the quarter ending June,... For our 2021 Integrated Report 2020 Marketing, Sales Management, Leadership, and is markets. Website uses cookies to enhance your browsing experience analysis and disclosed in &. Letter ; by: Ronak Patel DayQ & amp ; a Session about 2020 MediumTerm Business [! Strategic Planning news releases is current on the date of the announcement, but is to! +27 31 580 8600 should you have any queries Global Biodiversity Policy was created for sustainable Management Ipsen! Development reviews latest information on eisai 's sustainability activities 31, 2021 ) ]... Call +27 31 580 8600 should you have any queries history of working in the news releases current!